Advances in the Management of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): A Closer Look at the Integration of Immunotherapy

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 10, 2018 to June 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Merck & Company

Head and neck squamous cell carcinoma (HNSCC) affects the mouth, throat, and nasal cavity. The prognosis is fatal once the cancer metastasizes, giving patients, on average, about 5 years to survive. Symptoms may range from mouth ulcers, bleeding or pain the mouth, chronic sinus congestion, sore throat, pain when swallowing, and difficult breathing. Thankfully novel treatments in immunotherapies have proven efficacious, providing an increased survival rate and improved quality of life for patients.

Upon Completion of this activity, participants will be able to:

  • Analyze data on new immunotherapies for treatment of metastatic HNSCC after disease progression

  • Examine the role of anti–PD-1 immunotherapy in the management of metastatic HNSCC

  • Review immune-related adverse events & potential management strategies associated with the use of novel immunotherapy

  • Identify metastatic HNSCC patients who would potentially benefit from immunotherapies

Faculty: Ezra Cohen, MD
Associate Director
Professor of Medicine
UC San Diego Health - La Jolla
Moores Cancer Center


Dr. Cohen serves as a consultant to AstraZeneca, Bristol-Myers Squibb, Eisai, Human Longevity, Inc., Merck & Co, and Pfizer. His Presentation has been reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Merck & Company

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue